Growth factor IGF-Il

• US 5,482,926 A
• Filed: 02/17/1994
• Issued: 01/09/1996
• Est. Priority Date: 06/08/1992
• Status: Expired due to Fees

• Current Assignee: Pharmacia AB (Pharmacia Corp.)
• Original Assignee: Pharmacia AB (Pharmacia Corp.)
• Inventors: Mellor, David J., Gluckman, Peter D.
• Primary Examiner(s): Warden, Jill
• Assistant Examiner(s): TOUZEAU, LYNN
• Application Number:
  US08/190,168
• Time in Patent Office: 691 Days
• Field of Search: 514/12, 514/21, 530/303, 530/399
• US Class Current: 514/5.5
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to the use of iGF-II or effective analogues thereof for the manufacture of a medicament for prevention or treatment of nutritional or gastrointestinal disorders and for promoting human or animal neonatal growth. It also relates to composition comprising exogenous human or animal IGF-II or effective analogues thereof in a therapeutically effective amount together with a pharmaceutically acceptable carrier or diluent or foodstuff, preferably in admixture with artificial or natural milk or colostrum. The invention may be applied both in man and in animals.

Claims

1. Composition for the treatment of nutritional or gastrointestinal disorders or for promoting human or animal neonatal growth comprising human or animal IGF-II in a therapeutical effective amount together with a pharmaceutically acceptable carrier or diluent, wherein said carrier or diluent is for oral or gastric administration and wherein said carrier or diluent comprises natural milk or colorstrum.

2. The composition of claim 1 Wherein said carrier or diluent is for oral administration.

3. Composition according to claim 1 for promoting growth, thrift or nutrition in man or animals or reducing the risk of intestinal infection.

21. The composition of claim 1 which consists of said IGF-II as the active ingredient.

4. The method for the treatment of nutritional or gastrointestinal disorders or for promoting human or animal neonatal growth in a patient in need thereof which comprises administering to said patient a medicament for oral or gastric administration and wherein said carrier or diluent comprises natural milk or colostrum comprising a therapeutically effective amount of IGF-II.

5. The method of claim 4 wherein said IGF-II is human IGF-II.

6. The method of claim 4 wherein said IGF-II is animal IGF-II.

7. The method of claim 4 wherein said medicament is administered orally.

8. The method of claim 4 for promoting intestinal mucosal growth.

9. The method of claim 4 for promoting gastrointestinal muscle growth following surgery or in disorders of the gastrointestinal tract.

10. The method of claim 4 for restoring or maintaining gastrointestinal function after periods of parenteral nutrition or after gastrointestinal disease or to accelerate recovery.

11. The method of claim 4 for promoting villus growth and enhances nutritional status in patients with mucosal villous diseases.

12. The method of claim 4 for promoting growth of neonatal and premature human or animal.

13. The method of claim 12 for promoting growth and development of neonatal animals, growth of premature infants and reducing the risk of necrotizing enterocolitis and infection of gastrointestinal tract.

14. The method of claim 12 for promoting villous growth and enhanced nutritional status in premature infants or in growth retarded infants.

15. The method of claim 12 for reducing the risk of enteric disease.

16. The method of claim 10 wherein said disease is selected from the group consisting of gastroenteritis, inflammatory bowel disease, and bowel surgery ulceration of the duodenum.

17. The method of claim 11 wherein said mucosal villous diseases are selected from the group consisting of coeliac disease, past infective villous atrophy and short gut syndromes.

18. The method of claim 12 for reducing the risk of enteritis in a neonate.

19. The method of claim 4 wherein said patient is a neonate.

20. The method of claim 4 wherein said patient is a premature infant.

22. The method of claim 4 which consists of administering said IGF-II as the active ingredient.